FY2024 EPS Estimates for UroGen Pharma Boosted by Analyst

UroGen Pharma Ltd. (NASDAQ:URGN) – Investment analysts at HC Wainwright upped their FY2024 earnings estimates for UroGen Pharma in a research report issued on Thursday, November 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($3.01) for the year, up from their previous forecast of ($3.41). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q4 2024 earnings at ($0.65) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($3.06) EPS.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the previous year, the firm posted ($0.68) earnings per share.

URGN has been the topic of several other research reports. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Guggenheim initiated coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target on the stock. Finally, Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, UroGen Pharma has an average rating of “Buy” and an average price target of $48.38.

UroGen Pharma Stock Down 3.4 %

Shares of URGN opened at $12.35 on Monday. The stock has a 50 day moving average price of $12.73 and a 200 day moving average price of $14.16. UroGen Pharma has a one year low of $10.60 and a one year high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 7.93 and a current ratio of 9.00. The stock has a market capitalization of $289.61 million, a price-to-earnings ratio of -4.06 and a beta of 1.12.

Institutional Investors Weigh In On UroGen Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in shares of UroGen Pharma in the 2nd quarter valued at $719,000. Price T Rowe Associates Inc. MD acquired a new position in UroGen Pharma in the first quarter valued at about $4,008,000. Millennium Management LLC increased its position in shares of UroGen Pharma by 2,672.0% during the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after acquiring an additional 1,119,019 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after acquiring an additional 1,337,257 shares during the last quarter. Finally, Wesbanco Bank Inc. purchased a new position in shares of UroGen Pharma during the 3rd quarter worth approximately $945,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.